Jian Brian, Yang Isaac, Parsa Andrew T
Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, M779, San Francisco, CA 94143-0112, USA.
Neurosurg Clin N Am. 2010 Jan;21(1):195-9. doi: 10.1016/j.nec.2009.09.004.
Immunotherapy provides the ideal candidate of therapeutic attack against malignant gliomas because it allows for targeting of cancer cells without the potential for nonspecific toxicity. This is important when glial tumor cells spread far through normal brain tissue. Current vaccine therapies are in clinical trials and are showing beneficial responses. Given that the inflammatory response may make serial radiographic imaging more difficult to interpret, newer methodologies of immunomonitoring must be developed to assess the biologic efficacy of these immunotherapies. This article reviews methods of monitoring the immune system after vaccination against malignant gliomas. Improvements in immunomonitoring should lead to an increase in the efficiency of identifying viable avenues of therapeutic research, and assess the efficacy of those currently employed.
免疫疗法为治疗恶性胶质瘤提供了理想的治疗手段，因为它能够靶向癌细胞而不存在非特异性毒性的风险。当胶质肿瘤细胞在正常脑组织中广泛扩散时，这一点尤为重要。目前的疫苗疗法正在进行临床试验，并已显示出有益的反应。鉴于炎症反应可能使系列影像学检查结果更难以解读，必须开发更新的免疫监测方法来评估这些免疫疗法的生物学疗效。本文综述了针对恶性胶质瘤接种疫苗后监测免疫系统的方法。免疫监测的改进应能提高识别可行治疗研究途径的效率，并评估目前所采用方法的疗效。
